Healthcare / BiotechnologyNasdaqCM
$1.49
+0.07 (+4.93%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-27.9M · quality 68.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
22/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$11M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-92.3%
↓Gross Margin
N/A
•Debt/Equity
0.02
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2013–2025 · 12 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
1.08x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-17.5M · FCF $-19.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||||||
| Net Income | $-17.5M | $-17.5M | $-32.1M | $-50.3M | $-26.1M | $-130.2M | $-16.7M | $-2.4M | $-2.4M | $-1.3M | $-431923.00 | $-233008.00 | $-321896.00 | $-17510.00 |
| EBITDA | $-17.0M | $-17.0M | $-29.0M | $-45.7M | $-23.7M | — | — | — | — | — | — | — | — | — |
| EPS | -12.12 | -12.12 | -73.05 | -154.70 | -106.00 | -1482.00 | -685.00 | -98.00 | — | — | — | — | — | — |
| Balance Sheet | ||||||||||||||
| Debt/Equity | 0.02 | 0.02 | 0.39 | 0.94 | 3.34 | — | -0.00 | — | — | — | — | — | — | — |
| Current Ratio | 9.97 | 9.97 | — | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | ||||||||||||||
| Free Cash Flow | $-19.0M | $-19.0M | $-27.9M | $-40.3M | $-19.0M | — | — | — | — | — | — | — | — | — |
| Returns | ||||||||||||||
| ROE | -92.3% | -92.3% | -207.1% | -327.6% | -710.6% | -2579.0% | 77.6% | -114.7% | -2189.0% | -115.0% | -22.5% | 430.5% | -187.8% | -3.6% |
| Valuation | ||||||||||||||
| P/B | 0.12 | 0.12 | 1.19 | 9.40 | 9.27 | — | — | — | — | — | — | — | — | — |
| Growth & Yield | ||||||||||||||
| EPS Growth | 83.4% | 83.4% | 52.8% | -45.9% | — | -116.4% | -599.0% | — | — | — | — | — | — | — |
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-85.7%
Start / end P/E
n/dx → n/dx
EPS bridge
-73.05 → -12.12
Residual
-85.7%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.